Dietary supplementation with L-arginine in patients with breast cancer (> 4 cm) receiving multimodality treatment: Report of a feasibility study

J. Brittenden, S. D. Heys*, I. Miller, T. K. Sarkar, A. W. Hutcheon, G. Needham, F. Gilbert, M. McKean, A. K. Ah-See, O. Eremin

*Corresponding author for this work

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

L-Arginine has been shown, in human breast cancers, to increase protein synthesis and the number of cells in the growth phase of the cell cycle. L-Arginine, therefore, may potentiate the response of breast cancers to cell cycle-specific cytotoxic agents. This phase II pilot study assessed the clinical, radiological and pathological responses in 44 patients with breast cancers > 4 cm in diameter (46 tumours: T2, n = 6; T3, n = 22; T4, n = 19), who received oral L-arginine 30 g day-1 for 3 days prior to each cycle of CHOP chemotherapy, followed after 4-6 cycles by radiotherapy. Following this treatment, 95% of patients had a clinical response: Complete response in 30% and partial response in 65%. Imaging, ultrasound and mammography revealed response rates of 91% and 76% respectively. Surgery was performed in 43 patients. Histological examination revealed that in 18% of cases there was no residual evidence of tumour. Furthermore, if residual tumour was identified, the degree of destruction was graded as ‘severe’ in 36% and ‘moderate’ in 30% of cases. Further studies are now required to evaluate the potential beneficial use of nutritional pharmacology in combination with existing treatment regimens.

Original languageEnglish
Pages (from-to)918-921
Number of pages4
JournalBritish Journal of Cancer
Volume69
Issue number5
DOIs
Publication statusPublished - 1 May 1994

Fingerprint

Feasibility Studies
Dietary Supplements
Arginine
Residual Neoplasm
Breast Neoplasms
Cell Cycle
Mammary Ultrasonography
Cytotoxins
Radiotherapy
Therapeutics
Cell Proliferation
Pharmacology
Drug Therapy
Neoplasms
Proteins

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Dietary supplementation with L-arginine in patients with breast cancer (> 4 cm) receiving multimodality treatment : Report of a feasibility study. / Brittenden, J.; Heys, S. D.; Miller, I.; Sarkar, T. K.; Hutcheon, A. W.; Needham, G.; Gilbert, F.; McKean, M.; Ah-See, A. K.; Eremin, O.

In: British Journal of Cancer, Vol. 69, No. 5, 01.05.1994, p. 918-921.

Research output: Contribution to journalArticle

Brittenden, J, Heys, SD, Miller, I, Sarkar, TK, Hutcheon, AW, Needham, G, Gilbert, F, McKean, M, Ah-See, AK & Eremin, O 1994, 'Dietary supplementation with L-arginine in patients with breast cancer (> 4 cm) receiving multimodality treatment: Report of a feasibility study', British Journal of Cancer, vol. 69, no. 5, pp. 918-921. https://doi.org/10.1038/bjc.1994.177
Brittenden, J. ; Heys, S. D. ; Miller, I. ; Sarkar, T. K. ; Hutcheon, A. W. ; Needham, G. ; Gilbert, F. ; McKean, M. ; Ah-See, A. K. ; Eremin, O. / Dietary supplementation with L-arginine in patients with breast cancer (> 4 cm) receiving multimodality treatment : Report of a feasibility study. In: British Journal of Cancer. 1994 ; Vol. 69, No. 5. pp. 918-921.
@article{446adcb070604cf4987d7b56311304cb,
title = "Dietary supplementation with L-arginine in patients with breast cancer (> 4 cm) receiving multimodality treatment: Report of a feasibility study",
abstract = "L-Arginine has been shown, in human breast cancers, to increase protein synthesis and the number of cells in the growth phase of the cell cycle. L-Arginine, therefore, may potentiate the response of breast cancers to cell cycle-specific cytotoxic agents. This phase II pilot study assessed the clinical, radiological and pathological responses in 44 patients with breast cancers > 4 cm in diameter (46 tumours: T2, n = 6; T3, n = 22; T4, n = 19), who received oral L-arginine 30 g day-1 for 3 days prior to each cycle of CHOP chemotherapy, followed after 4-6 cycles by radiotherapy. Following this treatment, 95{\%} of patients had a clinical response: Complete response in 30{\%} and partial response in 65{\%}. Imaging, ultrasound and mammography revealed response rates of 91{\%} and 76{\%} respectively. Surgery was performed in 43 patients. Histological examination revealed that in 18{\%} of cases there was no residual evidence of tumour. Furthermore, if residual tumour was identified, the degree of destruction was graded as ‘severe’ in 36{\%} and ‘moderate’ in 30{\%} of cases. Further studies are now required to evaluate the potential beneficial use of nutritional pharmacology in combination with existing treatment regimens.",
author = "J. Brittenden and Heys, {S. D.} and I. Miller and Sarkar, {T. K.} and Hutcheon, {A. W.} and G. Needham and F. Gilbert and M. McKean and Ah-See, {A. K.} and O. Eremin",
year = "1994",
month = "5",
day = "1",
doi = "10.1038/bjc.1994.177",
language = "English",
volume = "69",
pages = "918--921",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Dietary supplementation with L-arginine in patients with breast cancer (> 4 cm) receiving multimodality treatment

T2 - Report of a feasibility study

AU - Brittenden, J.

AU - Heys, S. D.

AU - Miller, I.

AU - Sarkar, T. K.

AU - Hutcheon, A. W.

AU - Needham, G.

AU - Gilbert, F.

AU - McKean, M.

AU - Ah-See, A. K.

AU - Eremin, O.

PY - 1994/5/1

Y1 - 1994/5/1

N2 - L-Arginine has been shown, in human breast cancers, to increase protein synthesis and the number of cells in the growth phase of the cell cycle. L-Arginine, therefore, may potentiate the response of breast cancers to cell cycle-specific cytotoxic agents. This phase II pilot study assessed the clinical, radiological and pathological responses in 44 patients with breast cancers > 4 cm in diameter (46 tumours: T2, n = 6; T3, n = 22; T4, n = 19), who received oral L-arginine 30 g day-1 for 3 days prior to each cycle of CHOP chemotherapy, followed after 4-6 cycles by radiotherapy. Following this treatment, 95% of patients had a clinical response: Complete response in 30% and partial response in 65%. Imaging, ultrasound and mammography revealed response rates of 91% and 76% respectively. Surgery was performed in 43 patients. Histological examination revealed that in 18% of cases there was no residual evidence of tumour. Furthermore, if residual tumour was identified, the degree of destruction was graded as ‘severe’ in 36% and ‘moderate’ in 30% of cases. Further studies are now required to evaluate the potential beneficial use of nutritional pharmacology in combination with existing treatment regimens.

AB - L-Arginine has been shown, in human breast cancers, to increase protein synthesis and the number of cells in the growth phase of the cell cycle. L-Arginine, therefore, may potentiate the response of breast cancers to cell cycle-specific cytotoxic agents. This phase II pilot study assessed the clinical, radiological and pathological responses in 44 patients with breast cancers > 4 cm in diameter (46 tumours: T2, n = 6; T3, n = 22; T4, n = 19), who received oral L-arginine 30 g day-1 for 3 days prior to each cycle of CHOP chemotherapy, followed after 4-6 cycles by radiotherapy. Following this treatment, 95% of patients had a clinical response: Complete response in 30% and partial response in 65%. Imaging, ultrasound and mammography revealed response rates of 91% and 76% respectively. Surgery was performed in 43 patients. Histological examination revealed that in 18% of cases there was no residual evidence of tumour. Furthermore, if residual tumour was identified, the degree of destruction was graded as ‘severe’ in 36% and ‘moderate’ in 30% of cases. Further studies are now required to evaluate the potential beneficial use of nutritional pharmacology in combination with existing treatment regimens.

UR - http://www.scopus.com/inward/record.url?scp=0028346608&partnerID=8YFLogxK

U2 - 10.1038/bjc.1994.177

DO - 10.1038/bjc.1994.177

M3 - Article

C2 - 8180024

AN - SCOPUS:0028346608

VL - 69

SP - 918

EP - 921

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 5

ER -